See more : TH International Limited (THCH) Income Statement Analysis – Financial Results
Complete financial analysis of Intec Pharma Ltd (NTEC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intec Pharma Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- Thunderstruck Resources Ltd. (THURF) Income Statement Analysis – Financial Results
- Acciona, S.A. (ACXIF) Income Statement Analysis – Financial Results
- Banco di Desio e della Brianza S.p.A. (BDB.MI) Income Statement Analysis – Financial Results
- Genetics Generation Advancement Corp. (4160.TWO) Income Statement Analysis – Financial Results
- Beiersdorf Aktiengesellschaft (BEI.DE) Income Statement Analysis – Financial Results
Intec Pharma Ltd (NTEC)
About Intec Pharma Ltd
Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.74M | 26.66M | 35.40M | 24.30M | 10.75M | 4.79M | 3.41M | 2.59M |
| General & Administrative | 7.09M | 8.29M | 7.93M | 5.12M | 3.07M | 2.75M | 2.59M | 2.74M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.09M | 8.29M | 7.93M | 5.12M | 3.07M | 2.75M | 2.59M | 2.74M |
| Other Expenses | 0.00 | -1.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 13.83M | 33.45M | 43.33M | 29.41M | 13.82M | 7.54M | 6.00M | 5.33M |
| Cost & Expenses | 13.83M | 33.45M | 43.33M | 29.44M | 13.85M | 7.56M | 6.02M | 5.36M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 15.00K | 23.00K | 17.00K | 16.00K | 15.37K | 23.00K | 24.41K |
| Depreciation & Amortization | 1.20M | 854.00K | 859.00K | 829.00K | 701.00K | 742.38K | 585.00K | 624.84K |
| EBITDA | -12.80M | -46.09M | -42.56M | -28.22M | -12.65M | -6.39M | -5.09M | -4.63M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.83M | -33.45M | -43.33M | -29.44M | -13.85M | -7.56M | -6.02M | -5.36M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -175.00K | -13.52M | -112.00K | 375.00K | 484.00K | 421.40K | 325.00K | 74.66K |
| Income Before Tax | -14.00M | -46.96M | -43.44M | -29.06M | -13.36M | -7.14M | -5.69M | -5.28M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 124.00K | 638.00K | 103.00K | 29.00K | 500.00K | 436.77K | 348.00K | 99.07K |
| Net Income | -14.13M | -47.60M | -43.54M | -29.09M | -13.36M | -7.14M | -5.69M | -5.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -14.30 | -112.74 | -111.67 | -131.79 | -93.38 | -73.35 | -94.39 | -97.75 |
| EPS Diluted | -14.30 | -112.74 | -111.67 | -131.79 | -93.38 | -73.35 | -94.39 | -97.75 |
| Weighted Avg Shares Out | 988.00K | 422.20K | 389.91K | 220.75K | 143.10K | 97.39K | 60.31K | 54.03K |
| Weighted Avg Shares Out (Dil) | 988.00K | 422.20K | 389.91K | 220.75K | 143.10K | 97.39K | 60.31K | 54.03K |
Reviewing IMMURON LTD/S (NASDAQ:IMRN) and Intec Pharma (NASDAQ:NTEC)
30 Stocks Moving in Friday's Pre-Market Session
The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns
The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares
The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO
Intec Pharma to Participate at Upcoming June Conferences
Intec Pharma to Participate in the 29th Annual Roth Conference
Intec Pharma Granted Chinese Patent for Accordion PillTM Carbidopa / Levodopa
Intec Pharma to Participate in Upcoming September Conferences
Intec Pharma Granted European Patent for Accordion Pill™–Carbidopa / Levodopa
Source: https://incomestatements.info
Category: Stock Reports